Effectiveness and safety of apixaban versus warfarin in non‐valvular atrial fibrillation patients in “real‐world” clinical practice: A propensity matched analysis of 76,940 patients

Abstract The ARISTOTLE trial showed a risk reduction of stroke/systemic embolism (SE) and major bleeding in non-valvular atrial fibrillation (NVAF) patients treated with apixaban compared to warfarin. This retrospective study used four large US claims databases...

Real‐world comparison of major bleeding risk among NVAF patients initiated on apixaban, dabigatran, rivaroxaban, or warfarin: A propensity score matched analysis

Abstract Authors: Lip GYH, Keshishian A, Kamble S, Pan X, Mardekian J, Horblyuk R, Hamilton M. In addition to warfarin, there are four non-vitamin K antagonist oral anticoagulants (NOACs) available for stroke prevention in non valvular atrial fibrillation (NVAF)....